GLUCORA-2: Oral Semaglutide in Type 2 Diabetes

Evaluating the efficacy and safety of a once-daily oral GLP-1 therapy versus placebo in adults with type 2 diabetes inadequately controlled on metformin.

Key eligibility criteria

• Adults 18–70 years
• Diagnosed T2D ≥ 6 months
• HbA1c 7.0–10.5%
• Stable metformin dose ≥ 90 days

Additional criteria apply. A full eligibility review is completed by our coordinators during pre-screening — you may still qualify even if you're unsure about a criterion.